Related Experiment Video
Updated: Jan 12, 2026
Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
Published on: May 28, 2019
Immediate effect of intensive atorvastatin therapy on lipid parameters in patients with acute coronary syndrome
Dagmar Vondrakova1, Petr Ostadal, Andreas Kruger
1Cardiovascular Center, Department of Cardiology, Na Homolce Hospital, Prague, Czech Republic.
Insights
High-dose statin therapy initiated at acute coronary syndrome (ACS) admission significantly impacts lipid levels. While total cholesterol and LDL-cholesterol decrease, HDL-cholesterol drops and triglycerides rise acutely.
Area of Science:
- Cardiology
- Pharmacology
- Biochemistry
Background:
- Intensive statin therapy is proven to reduce mortality and coronary events post-acute coronary syndrome (ACS).
- The immediate impact of initiating high-dose statin therapy upon admission in ACS patients on lipid profiles remains unclear.
- Recent findings suggest lipid levels are stable during ACS before intervention.
Purpose of the Study:
- To investigate the immediate effects of high-dose atorvastatin therapy initiated at admission on lipid profiles in ACS patients.
- To compare the acute changes in total cholesterol, LDL-cholesterol, HDL-cholesterol, and triglycerides with established long-term treatment effects.
Main Methods:
- A cohort of 114 ACS patients received atorvastatin 80 mg upon admission and daily thereafter.
- Lipid levels (Total Cholesterol, LDL-C, HDL-C, Triglycerides) were measured at admission (D0) and on subsequent hospital days (D1, D2).
Main Results:
- Atorvastatin 80 mg significantly decreased Total Cholesterol (TC) by 6.1% (D1) and 13.2% (D2), and LDL-cholesterol (LDL) by 5.8% (D1) and 15.6% (D2) (p<0.001).
- HDL-cholesterol (HDL) levels decreased by 7.5% (D1) and 12.1% (D2) (p<0.001).
- Triglyceride (TG) levels significantly increased by 20.6% (D1) and 25.5% (D2) (p<0.05).
Conclusions:
- Intensive statin therapy initiated upon ACS admission exerts a rapid and significant effect on all measured lipid parameters.
- The observed acute decrease in HDL and increase in TG differ from expected long-term effects, suggesting a distinct short-term response to high-dose statins in ACS.
- These findings highlight the complex and immediate impact of early high-dose statin intervention on lipid metabolism during acute coronary events.
Background:
Intensive statin therapy decreases mortality and incidence of coronary events in patients after acute coronary syndrome (ACS). Recently it has been reported that spontaneous lipid levels remain clinically stable during ACS. The immediate influence of lipid levels by high-dose statin therapy initiated at admission in ACS patients is, however, not clear.
Methods:
We have analyzed a group of 114 patients with ACS (mean age 63.7; females 25.4%). Atorvastatin 80 mg was administered at admission and then once daily for the rest of hospitalization. The levels of total cholesterol (TC), LDL-cholesterol (LDL), HDL-cholesterol (HDL), and triglycerides (TG) were measured at admission (D0), and then every morning of hospitalization (D1, D2).
Results:
The mean entry values (D0) of TC, LDL, HDL and TG (in mmol/L) were 5.24, 3.26, 1.07 and 1.31, respectively. The therapy with atorvastatin 80 mg resulted in a decrease of TC levels in the first morning (D1) by 6.1% and in the second morning (D2) by 13.2% (p<0.001 for all comparisons with the entry value D0); LDL was decreased by 5.8% (D1) and 15.6% (D2) (p<0.001 vs. D0); the level of HDL was decreased by 7.5% (D1) and 12.1% (D2) (p<0.001 vs. D0). In contrast, the TG level was higher in the first morning (D1) by 20.6% and in the following morning (D2) by 25.5% (p<0.05 vs. D0).
Conclusions:
We have shown that intensive statin therapy started at admission in ACS patients has a highly significant, immediate effect on all monitored lipid levels. Since TC and LDL levels were decreased as predicted, reduction in HDL and increase in TG levels suggest a different acute effect of high-dose statin on lipid levels in comparison with long-term treatment of ACS patients.
